Multicenter trial of imipenem/cilastatin sodium combined with cefotiam hydrochloride in patients with MRSA infections

Kaoru Shimada; Shinichi Oka; Jingoro Shimada; Osamu Sakai; Masaru Yamamoto; Masao Hagiwara; Yosuke Ogura; Jingoro Shimada; Yasuo Idezuki; Toshiro Konishi; Hiroyoshi Kobayashi; Hideo Ikemoto; Hiroshi Isonuma; Takashi Inamatsu; Makiko Fukayama; Yoshishige Masuda; Tomiyoshi Sato; Yushi Uetera; Shigetomi Iwai; Koumei Kato; Hidekazu Tanaka; Issei Nakayama; Emiko Yamaji; Yozo Akieda; Tersuya Watanabe; Toshiaki Suzuki; Kanji Itokawa; Kota Okinaga; Hiroyuki Kobayashi; Shin Kawai; Masaaki Arakawa; Kouichi Wada; Jiro Yura; Nagao Shinagawa; Syu Ishikawa; Yuji Okada; Hiroshi Mizuno; Keiichi Hori; Susumu Watanabe; Toshiyuki Yamamoto; Kanzo Suzuki; Toshihiko Takeuchi; Yoshimitsu Hayashi; Kazuhide Yamamoto; Ikuji Usami; Kaoru Shimokata; Hidetaka Kawatsu; Kazuyoshi Senda; Hiroshi Amano; Hiroshi Saito; Hiroaki Kinoshita; Ken Morimoto; Shoji Kubo; Katsuji Sakai; Rinzo Soejima; Chikara Nakahama; Kunzo Orita; Eiji Konaga; Sadanori Fuchimoto; Hideyuki Kimura; Akio Hizuta; Yoshiro Sawae; Kaoru Okada; Hisashi Gondo; Masaru Nasu; Toru Yamasaki; Hiroyuki Nagai; Yoichiro Goto; Kohei Hara; Shigeru Kohno; Hironobu Koga; Mitsuo Kaku; Atsushi Saito; Yoshiteru Shigeno; Yuei Irabu; Hiroshi Fukuhara; Nobuchika Kusano; Matsuhisa Inoue

doi:10.11250/chemotherapy1953.40.654

Multicenter trial of imipenem/cilastatin sodium combined with cefotiam hydrochloride in patients with MRSA infections

Kaoru Shimada, Shinichi Oka, Jingoro Shimada, Osamu Sakai, Masaru Yamamoto, Masao Hagiwara, Yosuke Ogura, Jingoro Shimada, Yasuo Idezuki, Toshiro Konishi, Hiroyoshi Kobayashi, Hideo Ikemoto, Hiroshi Isonuma, Takashi Inamatsu, Makiko Fukayama, Yoshishige Masuda, Tomiyoshi Sato, Yushi Uetera, Shigetomi Iwai, Koumei KatoHidekazu Tanaka, Issei Nakayama, Emiko Yamaji, Yozo Akieda, Tersuya Watanabe, Toshiaki Suzuki, Kanji Itokawa, Kota Okinaga, Hiroyuki Kobayashi, Shin Kawai, Masaaki Arakawa, Kouichi Wada, Jiro Yura, Nagao Shinagawa, Syu Ishikawa, Yuji Okada, Hiroshi Mizuno, Keiichi Hori, Susumu Watanabe, Toshiyuki Yamamoto, Kanzo Suzuki, Toshihiko Takeuchi, Yoshimitsu Hayashi, Kazuhide Yamamoto, Ikuji Usami, Kaoru Shimokata, Hidetaka Kawatsu, Kazuyoshi Senda, Hiroshi Amano, Hiroshi Saito, Hiroaki Kinoshita, Ken Morimoto, Shoji Kubo, Katsuji Sakai, Rinzo Soejima, Chikara Nakahama, Kunzo Orita, Eiji Konaga, Sadanori Fuchimoto, Hideyuki Kimura, Akio Hizuta, Yoshiro Sawae, Kaoru Okada, Hisashi Gondo, Masaru Nasu, Toru Yamasaki, Hiroyuki Nagai, Yoichiro Goto, Kohei Hara, Shigeru Kohno, Hironobu Koga, Mitsuo Kaku, Atsushi Saito, Yoshiteru Shigeno, Yuei Irabu, Hiroshi Fukuhara, Nobuchika Kusano, Matsuhisa Inoue

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Sixty-six patients with confirmed or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with imipenem/cilastatin sodium (IPM/CS) 0.5 g every 12 hours combined with cefotiam hydrochloride (CTM) 2 g every 12 hours. The drugs were administered as either simultaneous or separate (IPM/CS→CTM) drip infusions. The results were as follows: 1) Using the checkerboard agar-dilution method the mean fractional inhibitory concentration (FIC) index of 48 strains of MRSA isolated before concomitant therapy with IPM and CTM was 0.217. 2) Bacteriologically, MRSA was eradicated in 23 patients, decreased in 10 and unchanged in 12. Superinfection occured in 6 patients, and the status of 2 was unknown. The eradication rate was 56.9%. 3) Fifteen (78.9%) of the 19 strains of organisms isolated concomitantly with MRSA were eradicated. More specifically, 7 of 10 strains of Pseudomonas aerginosa were eradicated. 4) Clinical cure was observed in 77.4% of the patients. Treatment was required because of respiratory tract infections in 29 patients including 25 with pneumonia), wound infections in 15, infections secondary to burns in 2, intra-abdominal infections in 2, subcutaneous infections in 2, intrapelvic infection in 1, urinary tract infection in 1 and sepsis in 1. 5) The overall clinical effect was excellent in 11 patients, good in 28 and poor in 12. The efficacy rate was 76.5%. 6) No statistically significant difference in overall clinical efficacy was observed between the simultaneous and separaee infusion protocols. 7) The coagulase type of the MRSA was II in the case of 23 strains, III in 16, IV in 3 and VII in 6. There were no statistically significant differences in efficacy rates among the various coagulase types. 8) Adverse effects observed clinically consisted of nausea in 2 patients, nausea and vomiting in 1 patient and diarrhea in 1 patient. Laboratory abverse events consisted of hepatic enzyme elevation in 8 patients. These abverse events were all mild and transient. In conclusion, IPM/CS combined with CTM is useful in the treatment of MRSA infections.

Original language	English
Pages (from-to)	654-672
Number of pages	19
Journal	CHEMOTHERAPY
Volume	40
Issue number	5
DOIs	https://doi.org/10.11250/chemotherapy1953.40.654
Publication status	Published - May 1992
Externally published	Yes

Keywords

MRSA
cefotiam hydrochloride
imipenem/cilastatin sodium

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology
Drug Discovery
Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.11250/chemotherapy1953.40.654

Cite this

Shimada, K., Oka, S., Shimada, J., Sakai, O., Yamamoto, M., Hagiwara, M., Ogura, Y., Shimada, J., Idezuki, Y., Konishi, T., Kobayashi, H., Ikemoto, H., Isonuma, H., Inamatsu, T., Fukayama, M., Masuda, Y., Sato, T., Uetera, Y., Iwai, S., ... Inoue, M. (1992). Multicenter trial of imipenem/cilastatin sodium combined with cefotiam hydrochloride in patients with MRSA infections. CHEMOTHERAPY, 40(5), 654-672. https://doi.org/10.11250/chemotherapy1953.40.654

Shimada, K, Oka, S, Shimada, J, Sakai, O, Yamamoto, M, Hagiwara, M, Ogura, Y, Shimada, J, Idezuki, Y, Konishi, T, Kobayashi, H, Ikemoto, H, Isonuma, H, Inamatsu, T, Fukayama, M, Masuda, Y, Sato, T, Uetera, Y, Iwai, S, Kato, K, Tanaka, H, Nakayama, I, Yamaji, E, Akieda, Y, Watanabe, T, Suzuki, T, Itokawa, K, Okinaga, K, Kobayashi, H, Kawai, S, Arakawa, M, Wada, K, Yura, J, Shinagawa, N, Ishikawa, S, Okada, Y, Mizuno, H, Hori, K, Watanabe, S, Yamamoto, T, Suzuki, K, Takeuchi, T, Hayashi, Y, Yamamoto, K, Usami, I, Shimokata, K, Kawatsu, H, Senda, K, Amano, H, Saito, H, Kinoshita, H, Morimoto, K, Kubo, S, Sakai, K, Soejima, R, Nakahama, C, Orita, K, Konaga, E, Fuchimoto, S, Kimura, H, Hizuta, A, Sawae, Y, Okada, K, Gondo, H, Nasu, M, Yamasaki, T, Nagai, H, Goto, Y, Hara, K, Kohno, S, Koga, H, Kaku, M, Saito, A, Shigeno, Y, Irabu, Y, Fukuhara, H, Kusano, N & Inoue, M 1992, 'Multicenter trial of imipenem/cilastatin sodium combined with cefotiam hydrochloride in patients with MRSA infections', CHEMOTHERAPY, vol. 40, no. 5, pp. 654-672. https://doi.org/10.11250/chemotherapy1953.40.654

@article{0e73024a637a4102a6ac7be59b4b3f4b,

title = "Multicenter trial of imipenem/cilastatin sodium combined with cefotiam hydrochloride in patients with MRSA infections",

abstract = "Sixty-six patients with confirmed or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with imipenem/cilastatin sodium (IPM/CS) 0.5 g every 12 hours combined with cefotiam hydrochloride (CTM) 2 g every 12 hours. The drugs were administered as either simultaneous or separate (IPM/CS→CTM) drip infusions. The results were as follows: 1) Using the checkerboard agar-dilution method the mean fractional inhibitory concentration (FIC) index of 48 strains of MRSA isolated before concomitant therapy with IPM and CTM was 0.217. 2) Bacteriologically, MRSA was eradicated in 23 patients, decreased in 10 and unchanged in 12. Superinfection occured in 6 patients, and the status of 2 was unknown. The eradication rate was 56.9%. 3) Fifteen (78.9%) of the 19 strains of organisms isolated concomitantly with MRSA were eradicated. More specifically, 7 of 10 strains of Pseudomonas aerginosa were eradicated. 4) Clinical cure was observed in 77.4% of the patients. Treatment was required because of respiratory tract infections in 29 patients including 25 with pneumonia), wound infections in 15, infections secondary to burns in 2, intra-abdominal infections in 2, subcutaneous infections in 2, intrapelvic infection in 1, urinary tract infection in 1 and sepsis in 1. 5) The overall clinical effect was excellent in 11 patients, good in 28 and poor in 12. The efficacy rate was 76.5%. 6) No statistically significant difference in overall clinical efficacy was observed between the simultaneous and separaee infusion protocols. 7) The coagulase type of the MRSA was II in the case of 23 strains, III in 16, IV in 3 and VII in 6. There were no statistically significant differences in efficacy rates among the various coagulase types. 8) Adverse effects observed clinically consisted of nausea in 2 patients, nausea and vomiting in 1 patient and diarrhea in 1 patient. Laboratory abverse events consisted of hepatic enzyme elevation in 8 patients. These abverse events were all mild and transient. In conclusion, IPM/CS combined with CTM is useful in the treatment of MRSA infections.",

keywords = "MRSA, cefotiam hydrochloride, imipenem/cilastatin sodium",

author = "Kaoru Shimada and Shinichi Oka and Jingoro Shimada and Osamu Sakai and Masaru Yamamoto and Masao Hagiwara and Yosuke Ogura and Jingoro Shimada and Yasuo Idezuki and Toshiro Konishi and Hiroyoshi Kobayashi and Hideo Ikemoto and Hiroshi Isonuma and Takashi Inamatsu and Makiko Fukayama and Yoshishige Masuda and Tomiyoshi Sato and Yushi Uetera and Shigetomi Iwai and Koumei Kato and Hidekazu Tanaka and Issei Nakayama and Emiko Yamaji and Yozo Akieda and Tersuya Watanabe and Toshiaki Suzuki and Kanji Itokawa and Kota Okinaga and Hiroyuki Kobayashi and Shin Kawai and Masaaki Arakawa and Kouichi Wada and Jiro Yura and Nagao Shinagawa and Syu Ishikawa and Yuji Okada and Hiroshi Mizuno and Keiichi Hori and Susumu Watanabe and Toshiyuki Yamamoto and Kanzo Suzuki and Toshihiko Takeuchi and Yoshimitsu Hayashi and Kazuhide Yamamoto and Ikuji Usami and Kaoru Shimokata and Hidetaka Kawatsu and Kazuyoshi Senda and Hiroshi Amano and Hiroshi Saito and Hiroaki Kinoshita and Ken Morimoto and Shoji Kubo and Katsuji Sakai and Rinzo Soejima and Chikara Nakahama and Kunzo Orita and Eiji Konaga and Sadanori Fuchimoto and Hideyuki Kimura and Akio Hizuta and Yoshiro Sawae and Kaoru Okada and Hisashi Gondo and Masaru Nasu and Toru Yamasaki and Hiroyuki Nagai and Yoichiro Goto and Kohei Hara and Shigeru Kohno and Hironobu Koga and Mitsuo Kaku and Atsushi Saito and Yoshiteru Shigeno and Yuei Irabu and Hiroshi Fukuhara and Nobuchika Kusano and Matsuhisa Inoue",

year = "1992",

month = may,

doi = "10.11250/chemotherapy1953.40.654",

language = "English",

volume = "40",

pages = "654--672",

journal = "CHEMOTHERAPY",

issn = "0009-3165",

number = "5",

}

TY - JOUR

T1 - Multicenter trial of imipenem/cilastatin sodium combined with cefotiam hydrochloride in patients with MRSA infections

AU - Shimada, Kaoru

AU - Oka, Shinichi

AU - Shimada, Jingoro

AU - Sakai, Osamu

AU - Yamamoto, Masaru

AU - Hagiwara, Masao

AU - Ogura, Yosuke

AU - Shimada, Jingoro

AU - Idezuki, Yasuo

AU - Konishi, Toshiro

AU - Kobayashi, Hiroyoshi

AU - Ikemoto, Hideo

AU - Isonuma, Hiroshi

AU - Inamatsu, Takashi

AU - Fukayama, Makiko

AU - Masuda, Yoshishige

AU - Sato, Tomiyoshi

AU - Uetera, Yushi

AU - Iwai, Shigetomi

AU - Kato, Koumei

AU - Tanaka, Hidekazu

AU - Nakayama, Issei

AU - Yamaji, Emiko

AU - Akieda, Yozo

AU - Watanabe, Tersuya

AU - Suzuki, Toshiaki

AU - Itokawa, Kanji

AU - Okinaga, Kota

AU - Kobayashi, Hiroyuki

AU - Kawai, Shin

AU - Arakawa, Masaaki

AU - Wada, Kouichi

AU - Yura, Jiro

AU - Shinagawa, Nagao

AU - Ishikawa, Syu

AU - Okada, Yuji

AU - Mizuno, Hiroshi

AU - Hori, Keiichi

AU - Watanabe, Susumu

AU - Yamamoto, Toshiyuki

AU - Suzuki, Kanzo

AU - Takeuchi, Toshihiko

AU - Hayashi, Yoshimitsu

AU - Yamamoto, Kazuhide

AU - Usami, Ikuji

AU - Shimokata, Kaoru

AU - Kawatsu, Hidetaka

AU - Senda, Kazuyoshi

AU - Amano, Hiroshi

AU - Saito, Hiroshi

AU - Kinoshita, Hiroaki

AU - Morimoto, Ken

AU - Kubo, Shoji

AU - Sakai, Katsuji

AU - Soejima, Rinzo

AU - Nakahama, Chikara

AU - Orita, Kunzo

AU - Konaga, Eiji

AU - Fuchimoto, Sadanori

AU - Kimura, Hideyuki

AU - Hizuta, Akio

AU - Sawae, Yoshiro

AU - Okada, Kaoru

AU - Gondo, Hisashi

AU - Nasu, Masaru

AU - Yamasaki, Toru

AU - Nagai, Hiroyuki

AU - Goto, Yoichiro

AU - Hara, Kohei

AU - Kohno, Shigeru

AU - Koga, Hironobu

AU - Kaku, Mitsuo

AU - Saito, Atsushi

AU - Shigeno, Yoshiteru

AU - Irabu, Yuei

AU - Fukuhara, Hiroshi

AU - Kusano, Nobuchika

AU - Inoue, Matsuhisa

PY - 1992/5

Y1 - 1992/5

N2 - Sixty-six patients with confirmed or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with imipenem/cilastatin sodium (IPM/CS) 0.5 g every 12 hours combined with cefotiam hydrochloride (CTM) 2 g every 12 hours. The drugs were administered as either simultaneous or separate (IPM/CS→CTM) drip infusions. The results were as follows: 1) Using the checkerboard agar-dilution method the mean fractional inhibitory concentration (FIC) index of 48 strains of MRSA isolated before concomitant therapy with IPM and CTM was 0.217. 2) Bacteriologically, MRSA was eradicated in 23 patients, decreased in 10 and unchanged in 12. Superinfection occured in 6 patients, and the status of 2 was unknown. The eradication rate was 56.9%. 3) Fifteen (78.9%) of the 19 strains of organisms isolated concomitantly with MRSA were eradicated. More specifically, 7 of 10 strains of Pseudomonas aerginosa were eradicated. 4) Clinical cure was observed in 77.4% of the patients. Treatment was required because of respiratory tract infections in 29 patients including 25 with pneumonia), wound infections in 15, infections secondary to burns in 2, intra-abdominal infections in 2, subcutaneous infections in 2, intrapelvic infection in 1, urinary tract infection in 1 and sepsis in 1. 5) The overall clinical effect was excellent in 11 patients, good in 28 and poor in 12. The efficacy rate was 76.5%. 6) No statistically significant difference in overall clinical efficacy was observed between the simultaneous and separaee infusion protocols. 7) The coagulase type of the MRSA was II in the case of 23 strains, III in 16, IV in 3 and VII in 6. There were no statistically significant differences in efficacy rates among the various coagulase types. 8) Adverse effects observed clinically consisted of nausea in 2 patients, nausea and vomiting in 1 patient and diarrhea in 1 patient. Laboratory abverse events consisted of hepatic enzyme elevation in 8 patients. These abverse events were all mild and transient. In conclusion, IPM/CS combined with CTM is useful in the treatment of MRSA infections.

AB - Sixty-six patients with confirmed or suspected methicillin-resistant Staphylococcus aureus (MRSA) infections were treated with imipenem/cilastatin sodium (IPM/CS) 0.5 g every 12 hours combined with cefotiam hydrochloride (CTM) 2 g every 12 hours. The drugs were administered as either simultaneous or separate (IPM/CS→CTM) drip infusions. The results were as follows: 1) Using the checkerboard agar-dilution method the mean fractional inhibitory concentration (FIC) index of 48 strains of MRSA isolated before concomitant therapy with IPM and CTM was 0.217. 2) Bacteriologically, MRSA was eradicated in 23 patients, decreased in 10 and unchanged in 12. Superinfection occured in 6 patients, and the status of 2 was unknown. The eradication rate was 56.9%. 3) Fifteen (78.9%) of the 19 strains of organisms isolated concomitantly with MRSA were eradicated. More specifically, 7 of 10 strains of Pseudomonas aerginosa were eradicated. 4) Clinical cure was observed in 77.4% of the patients. Treatment was required because of respiratory tract infections in 29 patients including 25 with pneumonia), wound infections in 15, infections secondary to burns in 2, intra-abdominal infections in 2, subcutaneous infections in 2, intrapelvic infection in 1, urinary tract infection in 1 and sepsis in 1. 5) The overall clinical effect was excellent in 11 patients, good in 28 and poor in 12. The efficacy rate was 76.5%. 6) No statistically significant difference in overall clinical efficacy was observed between the simultaneous and separaee infusion protocols. 7) The coagulase type of the MRSA was II in the case of 23 strains, III in 16, IV in 3 and VII in 6. There were no statistically significant differences in efficacy rates among the various coagulase types. 8) Adverse effects observed clinically consisted of nausea in 2 patients, nausea and vomiting in 1 patient and diarrhea in 1 patient. Laboratory abverse events consisted of hepatic enzyme elevation in 8 patients. These abverse events were all mild and transient. In conclusion, IPM/CS combined with CTM is useful in the treatment of MRSA infections.

KW - MRSA

KW - cefotiam hydrochloride

KW - imipenem/cilastatin sodium

UR - http://www.scopus.com/inward/record.url?scp=0026769182&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026769182&partnerID=8YFLogxK

U2 - 10.11250/chemotherapy1953.40.654

DO - 10.11250/chemotherapy1953.40.654

M3 - Article

AN - SCOPUS:0026769182

SN - 0009-3165

VL - 40

SP - 654

EP - 672

JO - CHEMOTHERAPY

JF - CHEMOTHERAPY

IS - 5

ER -

Multicenter trial of imipenem/cilastatin sodium combined with cefotiam hydrochloride in patients with MRSA infections

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this